Medical Oncologist
Medicines
How does trastuzumab emtansine work, and who is it for?
Trastuzumab emtansine joins a HER2 antibody to a chemotherapy medicine, so the chemotherapy is carried mainly to HER2-positive cancer cells and released inside them. It is used after surgery when invasive cancer remains despite earlier treatment, and for advanced HER2-positive breast cancer already treated with other HER2 medicines. This page explains how it works.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed September 2026, next review due September 2027
On this page
- How does trastuzumab emtansine work, and who is it for?
- How T-DM1 reaches and acts on cancer cells
- Where T-DM1 fits in breast cancer treatment
- The vocabulary, in plain language
- Honest limits of a targeted treatment
- Why T-DM1 is used when cancer remains after surgery
- Where T-DM1 fits when cancer has spread
- What people assume about how T-DM1 works
- Common questions about how trastuzumab emtansine works
The short answer
How does trastuzumab emtansine work, and who is it for?
Trastuzumab emtansine, also called T-DM1 or Kadcyla, is a type of medicine called an antibody-drug conjugate. It combines two parts in one molecule. The first part is trastuzumab, an antibody that recognises HER2, a protein found in large amounts on the surface of HER2-positive breast cancer cells. The second part is DM1, a strong chemotherapy medicine, held on to the antibody by a stable chemical link. When T-DM1 is given through a drip, the antibody seeks out cells with plenty of HER2 and attaches to them. The cell then draws the whole molecule inside, where it is broken down and the chemotherapy is released. The chemotherapy disrupts the internal scaffolding the cell needs to divide, so the cell stops growing and dies. The antibody part may also keep some of the effects of trastuzumab itself, such as blocking HER2 growth signals and helping the immune system recognise cancer cells. Because most of the chemotherapy is delivered to cells rich in HER2, healthy cells are exposed to less of it than with standard chemotherapy, although some side effects still occur. T-DM1 is used for HER2-positive breast cancer in two main situations: after surgery, when some invasive cancer remained despite chemotherapy and HER2 treatment given before the operation, and for advanced cancer that has already been treated with trastuzumab and chemotherapy. It is not used for HER2-negative cancer.
An antibody with a chemotherapy payload
The antibody acts as a guide, carrying chemotherapy to cells that carry a lot of HER2.
Released inside the cancer cell
The chemotherapy is mainly set free once the molecule is inside the target cell.
Only for HER2-positive cancer
Your pathology report must show HER2-positive cancer for T-DM1 to be considered.
This page gives general information only. Whether T-DM1 suits you depends on your cancer, earlier treatment and health, as judged by your own team.Four steps
How T-DM1 reaches and acts on cancer cells
A simple way to picture what happens after the drip.
Finding the target
The trastuzumab part travels in the blood and attaches to HER2 proteins on the surface of cancer cells.
Being taken inside
The cell pulls the attached molecule inside, a normal process cells use to take in proteins from their surroundings.
Cells with little HER2 take up much less of the medicine.Releasing the chemotherapy
Inside the cell, the antibody is broken down, freeing the part of the molecule that carries DM1.
Stopping cell division
DM1 disrupts the fibres a cell needs to split in two, so the cancer cell cannot divide and dies.
Extra effects of the antibody
- Blocking HER2 growth signals
- Helping immune cells recognise the cancer
- Keeping the chemotherapy close to its target
Who it is for
Where T-DM1 fits in breast cancer treatment
Situation
How T-DM1 is generally used
Early HER2-positive cancer with cancer left after chemotherapy and surgery
Given instead of continuing trastuzumab, usually for fourteen cycles
Early HER2-positive cancer fully cleared before surgery
Not usually needed; trastuzumab-based treatment continues
Advanced HER2-positive cancer after earlier HER2 treatment
One of the options, often used after other HER2 medicines
HER2-low or HER2-negative cancer
Not used; other medicines are considered
Pregnancy
Not given, because it can harm an unborn baby
Words you will hear
The vocabulary, in plain language
- HER2
- A protein that helps cells grow. Some breast cancers make far too much of it.
- Antibody-drug conjugate
- A medicine that joins an antibody to a chemotherapy medicine to deliver it to specific cells.
- Trastuzumab
- An antibody that attaches to HER2. It forms the guiding part of T-DM1.
- DM1
- The chemotherapy part of T-DM1, related to a medicine called maytansine.
- Residual disease
- Invasive cancer still found in the breast or lymph nodes at surgery after treatment given before the operation.
- Neoadjuvant treatment
- Chemotherapy and HER2 treatment given before surgery to shrink the cancer.
Talk to our team
Have a question about your situation?
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Being straight with you
Honest limits of a targeted treatment
The idea of a guided chemotherapy is appealing, and T-DM1 is an important medicine. It also has real limits.
Targeted is not the same as side-effect free
Some chemotherapy still reaches healthy tissues, which is why low platelets, liver changes, tiredness and nerve changes happen.
Not every cancer responds
Some HER2-positive cancers resist T-DM1 from the start or stop responding over time, and the reasons are not fully understood.
It lowers risk rather than removing it
After surgery, T-DM1 lowers the chance of the cancer returning, but it cannot rule out a recurrence.
What this page cannot tell you
It cannot tell you whether T-DM1 is the right choice for your cancer, or how well it will work for you. Your oncologist can explain that.
Early breast cancer
Why T-DM1 is used when cancer remains after surgery
Many people with HER2-positive breast cancer have chemotherapy and HER2 treatment before surgery. If the operation shows no invasive cancer left, the outlook is generally very good. If some invasive cancer remains, the risk of it returning is higher.
What research showed
A large international study compared T-DM1 with continuing trastuzumab in people with remaining cancer after this treatment. T-DM1 lowered the chance of the cancer coming back, and longer follow-up also suggested people lived longer.
Alongside other treatment
Radiotherapy and hormone tablets, if your cancer is also hormone receptor-positive, are often given at the same time.
If T-DM1 cannot be continued
If side effects stop treatment early, many people complete their year of HER2 treatment with trastuzumab instead.
Advanced breast cancer
Where T-DM1 fits when cancer has spread
For advanced HER2-positive breast cancer, several HER2 medicines are now available, and the order they are used in depends on earlier treatment, availability and your health.
Its established role
T-DM1 was shown to help people whose advanced cancer had already been treated with trastuzumab and a taxane chemotherapy, controlling the cancer for longer than an older combination.
Newer options
Trastuzumab deruxtecan, a newer related medicine, is now often preferred earlier where it is available, so T-DM1 may be used later in the sequence.
Ongoing treatment
In advanced cancer, T-DM1 usually continues while it keeps the cancer controlled and side effects remain manageable.
Commonly believed
What people assume about how T-DM1 works
T-DM1 is simply trastuzumab under another name.
It contains trastuzumab joined to a chemotherapy medicine, so it works and is dosed differently.
Targeted medicines only affect cancer cells.
Most of the chemotherapy goes to HER2-rich cells, but some reaches healthy tissue too.
It can work for any breast cancer.
It is used for HER2-positive breast cancer, not for HER2-negative disease.
T-DM1 is the same as trastuzumab deruxtecan.
They are separate medicines with different chemotherapy parts and uses.
Questions we are asked
Common questions about how trastuzumab emtansine works
Is T-DM1 a chemotherapy?
It contains a chemotherapy medicine, DM1, joined to a HER2 antibody. So it is partly chemotherapy and partly targeted therapy. Because the chemotherapy is mostly delivered to HER2-rich cells, many people find it gentler than standard chemotherapy, though it still has side effects that need monitoring.
How do I know if my cancer is HER2-positive?
Your biopsy or surgery sample is tested in the laboratory. The pathology report will state whether the cancer is HER2-positive, sometimes after a second test called in situ hybridisation. Ask your team to show you the result if you are unsure.
Why is T-DM1 given instead of trastuzumab after surgery?
When invasive cancer remains after chemotherapy and HER2 treatment before surgery, the risk of recurrence is higher. Research showed switching to T-DM1 lowered that risk more than continuing trastuzumab alone. It replaces trastuzumab for the rest of the planned HER2 treatment.
Is T-DM1 given with pertuzumab?
Usually not. T-DM1 already contains a HER2 antibody, and adding pertuzumab has not been shown to add enough benefit in most situations. Your team will explain which HER2 medicines are planned for each stage of your treatment.
Can it be given if my cancer is also hormone receptor-positive?
Yes. Many HER2-positive cancers are also hormone receptor-positive. In that case, hormone tablets are often taken alongside T-DM1 after surgery, and continue for years afterwards. Your team will plan both treatments together.
Does T-DM1 work on cancer in the brain?
Large antibody medicines do not cross into the brain easily, although some effect on brain metastases has been reported. Other treatments, such as radiotherapy, surgery or tablets that reach the brain more easily, are often considered. Your team can explain the options.
Who should not have T-DM1?
It is not given during pregnancy or to people with HER2-negative cancer. Caution is needed if heart pumping strength is low, platelets are already low, or there is significant liver or lung disease. Your team checks these before starting.
How do I know if it is working?
After surgery, there is no cancer to measure, so success means no recurrence over time. In advanced cancer, scans every few months, along with symptoms and sometimes blood tests, show whether the cancer is controlled. Side effects do not indicate whether it is working.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Where to find us
Our centres in and around Hyderabad
Addressed by landmark, because that is how this city navigates. Each centre also names the areas it serves, so you can place it without a map. Consultation and day-care Chemotherapy run at every one of them.
Warangal
Vizag
Talk to our team
Speak to a breast cancer specialist
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Sources
- National Cancer Institute — Ado-trastuzumab emtansine
- European Medicines Agency — Kadcyla: product information
- Cancer Research UK — Trastuzumab emtansine (Kadcyla)
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.